Editas Medicine

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant Both patients…

Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach…

SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in…

Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels Treated eyes showed morphological and…

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for…

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid…

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical…

No serious adverse events or dose-limiting toxicities observed to date Efficacy signals in the mid-dose cohort provide initial support for clinical benefits Treatment in the adult…

IDMC endorsed proceeding with first pediatric cohort based on a review of clinical safety data from adult low-dose and adult mid-dose cohorts Concurrently enrolling the adult high-dose…

Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved…